Article: Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleSerum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B
AuthorsHui, CK1
Zhang, HY1
Lee, NP1
Chan, W1
Yueng, YH1
Leung, KW1
Lu, L1
Leung, N2
Lo, CM1
Fan, ST1
Luk, JM1
Xu, A1
Lam, KS1
Kwong, YL1
Lau, GKK1
KeywordsAdiponectin
Adiponectin oligomeric form
Chronic hepatitis B
Lamivudine
Liver cirrhosis
Pegylated interferon alfa-2a
Sustained virological response
Issue Date2007
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
CitationJournal Of Hepatology, 2007, v. 47 n. 2, p. 191-202 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2007.02.023
AbstractBackground/Aims: Despite the possible role of adiponectin in the pathogenesis of liver cirrhosis, few data have been collected from patients in different stages of liver fibrosis. We studied the role of adiponectin in 2 chronic hepatitis B (CHB)-patient cohorts. Methods: Serum adiponectin was quantified by enzyme-linked immunosorbent assay. One-hundred liver biopsy specimens from CHB patients with different stages of fibrosis and 38 paired liver biopsies from hepatitis B e antigen-positive patients randomized to lamivudine (n = 15), pegylated interferon alfa-2a (n = 15) or pegylated interferon alfa-2a plus lamivudine (n = 8) therapy for 48 weeks were assessed. Results: Serum adiponectin was detected at levels ranging over fourfold magnitude with advancing fibrosis stage and correlated positively with fibrosis stage [r = 0.45, p < 0.001]. CHB patients with stage 0-1 fibrosis had higher composition of high molecular weight (HMW) form of adiponectin when compared with CHB patients with liver cirrhosis [mean ± SEM 51.2 ± 2.1% vs. 40.9 ± 1.7%, respectively, p = 0.001]. After antiviral therapy, patients with fibrosis reduction had marked decline in serum adiponectin level and increase in HMW form of adiponectin [mean ± SEM 43.5 ± 1.2% vs. 37.0 ± 3.0%, respectively, p = 0.04]. Conclusions: Serum adiponectin may have a role in fibrosis progression in CHB infection. A marked decline in serum adiponectin after antiviral therapy is associated with fibrosis reduction. © 2007 European Association for the Study of the Liver.
ISSN0168-8278
2011 Impact Factor: 9.264
2011 SCImago Journal Rankings: 0.765
DOIhttp://dx.doi.org/10.1016/j.jhep.2007.02.023
ISI Accession Number IDWOS:000248642400006
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorHui, CK
dc.contributor.authorZhang, HY
dc.contributor.authorLee, NP
dc.contributor.authorChan, W
dc.contributor.authorYueng, YH
dc.contributor.authorLeung, KW
dc.contributor.authorLu, L
dc.contributor.authorLeung, N
dc.contributor.authorLo, CM
dc.contributor.authorFan, ST
dc.contributor.authorLuk, JM
dc.contributor.authorXu, A
dc.contributor.authorLam, KS
dc.contributor.authorKwong, YL
dc.contributor.authorLau, GKK
dc.date.accessioned2010-09-06T07:34:30Z
dc.date.available2010-09-06T07:34:30Z
dc.date.issued2007
dc.description.abstractBackground/Aims: Despite the possible role of adiponectin in the pathogenesis of liver cirrhosis, few data have been collected from patients in different stages of liver fibrosis. We studied the role of adiponectin in 2 chronic hepatitis B (CHB)-patient cohorts. Methods: Serum adiponectin was quantified by enzyme-linked immunosorbent assay. One-hundred liver biopsy specimens from CHB patients with different stages of fibrosis and 38 paired liver biopsies from hepatitis B e antigen-positive patients randomized to lamivudine (n = 15), pegylated interferon alfa-2a (n = 15) or pegylated interferon alfa-2a plus lamivudine (n = 8) therapy for 48 weeks were assessed. Results: Serum adiponectin was detected at levels ranging over fourfold magnitude with advancing fibrosis stage and correlated positively with fibrosis stage [r = 0.45, p < 0.001]. CHB patients with stage 0-1 fibrosis had higher composition of high molecular weight (HMW) form of adiponectin when compared with CHB patients with liver cirrhosis [mean ± SEM 51.2 ± 2.1% vs. 40.9 ± 1.7%, respectively, p = 0.001]. After antiviral therapy, patients with fibrosis reduction had marked decline in serum adiponectin level and increase in HMW form of adiponectin [mean ± SEM 43.5 ± 1.2% vs. 37.0 ± 3.0%, respectively, p = 0.04]. Conclusions: Serum adiponectin may have a role in fibrosis progression in CHB infection. A marked decline in serum adiponectin after antiviral therapy is associated with fibrosis reduction. © 2007 European Association for the Study of the Liver.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationJournal Of Hepatology, 2007, v. 47 n. 2, p. 191-202 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2007.02.023
dc.identifier.doihttp://dx.doi.org/10.1016/j.jhep.2007.02.023
dc.identifier.epage202
dc.identifier.hkuros133098
dc.identifier.isiWOS:000248642400006
dc.identifier.issn0168-8278
2011 Impact Factor: 9.264
2011 SCImago Journal Rankings: 0.765
dc.identifier.issue2
dc.identifier.openurl
dc.identifier.pmid17462782
dc.identifier.scopuseid_2-s2.0-34347389866
dc.identifier.spage191
dc.identifier.urihttp://hdl.handle.net/10722/77676
dc.identifier.volume47
dc.languageeng
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
dc.publisher.placeNetherlands
dc.relation.ispartofJournal of Hepatology
dc.relation.referencesReferences in Scopus
dc.rightsJournal of Hepatology. Copyright © Elsevier BV.
dc.subject.meshAdiponectin - blood - chemistry - genetics
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntiviral Agents - therapeutic use
dc.subject.meshCohort Studies
dc.subject.meshDisease Progression
dc.subject.meshEnzyme-Linked Immunosorbent Assay
dc.subject.meshFemale
dc.subject.meshHepatitis B, Chronic - complications - drug therapy - pathology
dc.subject.meshHumans
dc.subject.meshImmunohistochemistry
dc.subject.meshLiver - metabolism
dc.subject.meshLiver Cirrhosis - blood - metabolism - pathology - virology
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMolecular Weight
dc.subject.meshRNA, Messenger - metabolism
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction
dc.subject.meshSeverity of Illness Index
dc.subjectAdiponectin
dc.subjectAdiponectin oligomeric form
dc.subjectChronic hepatitis B
dc.subjectLamivudine
dc.subjectLiver cirrhosis
dc.subjectPegylated interferon alfa-2a
dc.subjectSustained virological response
dc.titleSerum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Alice Ho Miu Ling Nethersole Hospital